Industry Collaborators

Merck Logo


OncoSec Medical Inc. entered into a clinical collaboration with the University of California, San Francisco to evaluate the safety, tolerability, and efficacy of the combination of KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, and OncoSec’s ImmunoPulse® IL-12 in metastatic melanoma. Read the Press Release »


Heat Biologics

OncoSec Medical Inc. and Heat Biologics, Inc. entered into a collaboration to evaluate the combination of the immunotherapy approaches developed by each company. The companies will jointly evaluate the preclinical efficacy of OncoSec’s core technology, ImmunoPulse® with Heat’s proprietary gp-96-Ig based ImPACT immunotherapy platform. Read the Press Release »


PerkinElmer, Inc.

OncoSec Medical Inc. announced a collaboration with PerkinElmer, Inc. and the University of California, Los Angeles to help researchers develop biomarker tests to evaluate a patient’s immune response to cancer. The approach uses Perkin Elmer’s new imaging-based staining methods to quantitatively evaluate CD8+ T cell density in tumor biopsies. Read the Press Release »


Plexxikon Inc.

OncoSec Medical Inc. announced a pre-clinical collaboration with Plexxikon Inc., a member of the Daiichi Sankyo Group and leader in the discovery and development of novel small molecule and pharmaceuticals, to test the combination of Plexxikon’s selective CSF-1R inhibitor with OncoSec’s ImmunoPulse® IL-12. Read the Press Release »

Real Time Web Analytics